Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
Intrinsic Value
Maravai Lifesciences Holdings, Inc. is a life sciences company. [ Read More ]
The intrinsic value of one
MRVI
stock under the Base Case scenario is
3.72
USD.
Compared to the current market price of 7.7 USD,
Maravai LifeSciences Holdings Inc
is
Overvalued by 52%.
MRVI's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
MRVI or that its price is influenced by factors unrelated to fundamentals.
Maravai LifeSciences Holdings Inc's market capitalization is 1.9B USD.
MRVI stock price is 7.7 USD.
MRVI stock (3.72 USD) is 52% less than its price (7.7 USD).
MRVI stock (6.21 USD) is 19% less than its price (7.7 USD). Open Relative Valuation
MRVI has upside potential of 30% compared to the average analyst price target.
Open Wall St Estimates
MRVI's Revenue is forecast to grow at a rate of 7% per year over the next 3 years.
MRVI has negative Net Income for the last twelve months.
MRVI's D/E (Debt to Equity) is equal to 1.32.
MRVI's long-term assets (1B USD) exceed its long-term liabilties (1B USD).
MRVI's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 0%.
MRVI has negative Net Debt. This means that the company has more cash and short-term investments (575m USD) than debt (551m USD).
MRVI's Revenue has dropped by 67% over the past 12 months.
MRVI has very high three-year average ROIC (Return on Invested Capital): 26%. The company is very efficient at using invested capital to generate operating income.
MRVI has negative Operating Income for the last twelve months.
MRVI's ROE (Return on Equity) for the past 12 months is negative and is equal to -25%.
MRVI has positive Gross Profit for the last twelve months.
MRVI's Altman Z-Score is very low and is equal to 1.36.
MRVI has positive Free Cash Flow for the last twelve months.
MRVI has very high three-year average ROE (Return on Equity): 49%. The company is very efficient at transforming stockholders' equity into net income.
MRVI's short-term assets (700m USD) exceed its short-term liabilties (87m USD).
MRVI doesn't generate enough operating income (-25m USD) to safely cover interest payments on its debt (44m USD).
Valuation Backtest
Maravai LifeSciences Holdings Inc
Run backtest to discover the historical profit from buying and selling
MRVI
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Maravai LifeSciences Holdings Inc
Balance Sheet Decomposition
Maravai LifeSciences Holdings Inc
| Current Assets | 699.9m |
| Cash & Short-Term Investments | 575m |
| Receivables | 55.7m |
| Other Current Assets | 69.2m |
| Non-Current Assets | 787.5m |
| PP&E | 222.6m |
| Intangibles | 547m |
| Other Non-Current Assets | 17.9m |
| Current Liabilities | 87.5m |
| Accounts Payable | 10.7m |
| Accrued Liabilities | 56.6m |
| Other Current Liabilities | 20.2m |
| Non-Current Liabilities | 983.2m |
| Long-Term Debt | 550.6m |
| Other Non-Current Liabilities | 432.6m |
Earnings Waterfall
Maravai LifeSciences Holdings Inc
|
Revenue
|
288.9m
USD
|
|
Cost of Revenue
|
-148.7m
USD
|
|
Gross Profit
|
140.2m
USD
|
|
Operating Expenses
|
-165.4m
USD
|
|
Operating Income
|
-25.2m
USD
|
|
Other Expenses
|
-93.8m
USD
|
|
Net Income
|
-119m
USD
|
Free Cash Flow Analysis
Maravai LifeSciences Holdings Inc
MRVI Profitability Score
Profitability Due Diligence
Maravai LifeSciences Holdings Inc's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
Score
Maravai LifeSciences Holdings Inc's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
MRVI Solvency Score
Solvency Due Diligence
Maravai LifeSciences Holdings Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Maravai LifeSciences Holdings Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MRVI Price Targets Summary
Maravai LifeSciences Holdings Inc
According to Wall Street analysts, the average 1-year price target for
MRVI
is 9.98 USD
with a low forecast of 6.57 USD and a high forecast of 15.75 USD.
Ownership
MRVI Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
MRVI Price
Maravai LifeSciences Holdings Inc
| Average Annual Return | -6.38% |
| Standard Deviation of Annual Returns | 55.53% |
| Max Drawdown | -92% |
| Market Capitalization | 1.9B USD |
| Shares Outstanding | 251 400 000 |
| Percentage of Shares Shorted | 4.64% |
Company Profile
Maravai LifeSciences Holdings Inc
Country
Industry
Market Cap
Dividend Yield
Description
Maravai Lifesciences Holdings, Inc. is a life sciences company. The company is headquartered in San Diego, California and currently employs 470 full-time employees. The company went IPO on 2020-11-20. The firm provides products that enables the development of drug therapies, diagnostics, vaccines and support research on human diseases. The firm's segments include Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The company also provides research products for labeling and detecting proteins in cells and tissue samples. Its products include CleanCap, messenger ribonucleic acid (mRNA) and oligonucleotide. The Biologics Safety Testing focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing spectrum. The firm provides ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
MRVI
stock under the Base Case scenario is
3.72
USD.
Compared to the current market price of 7.7 USD,
Maravai LifeSciences Holdings Inc
is
Overvalued by 52%.
You don't have any saved screeners yet
